Key points for investors:
- Regulatory development: Management welcomed the federal rescheduling of medical cannabis to Schedule III and expects this to enable interstate commerce and potential international export for companies with DEA registration. Glass House has converted its cultivation and processing licenses to medical, submitted DEA Form 225 applications, completed an export application, and is engaging California regulators on tracking/tax for out-of-state sales.
- Large addressable opportunity: Management believes California-grown cannabis could command materially higher pricing outside California (including Europe) and that exports or interstate sales would meaningfully improve margins and cash generation. They are also progressing toward GACP compliance for potential European medical supply.
- Operations & expansion: The company is accelerating greenhouse buildouts. Greenhouse 2 (final 2/3) is coming online to contribute in H2; Greenhouse 4 is producing hemp with initial harvests planned for sale this summer. Full-year production target remains ~1 million pounds of biomass in 2026.
- Near-term execution issues: Q1 underperformance was driven by higher-than-expected production costs caused by reliance on less-experienced third-party labor contractors, simultaneous training and expansion activities, and the learning curve of rescaling to pre-raid production. Management expects costs to decline through the year as teams gain experience.
- Q1 2026 financials (preliminary): revenue $40.5M (ahead of prior guidance but down YoY), biomass production 152k lbs (ahead of guidance), average selling price $171/ lb, production cost $175/ lb, consolidated gross margin 25%, adjusted EBITDA negative $4.2M, ending cash ~$27.9M (includes proceeds from ATM issuance). Operating cash flow was negative $11.8M.
- Updated guidance & targets: Full-year revenue guidance reiterated at $235–245M and production target ~1M lbs. Updated average cost of production guidance increased to about $111/ lb (prior ~$100), with an unchanged long-term quarterly target of $95/ lb to be achieved in H2. Full-year adjusted EBITDA now expected in the high $30M range (down from prior high $40M guidance). Ending 2026 cash now expected in the low $40M range (down from ~ $50M prior). Hemp and any export/interstate sales are excluded from current guidance and would be incremental.
- Retail JV: Announced a 50/50 California retail joint venture with Vireo Growth to combine dispensary and delivery operations; expected to close in 2026 with minimal capital contribution from Glass House and a 5-year off-ramp option.
- Balance sheet & financing: Q1 included ~$3.5M CapEx and ~$2.9M paid in dividends. Company established a new $50M ATM facility (no current plans to use). Management is evaluating tax implications of rescheduling, with a sizable uncertain tax provision that may change if recreational rescheduling occurs.
- Investor engagement: Management reiterated confidence in long-term cost targets, emphasized the strategic optionality from rescheduling and hemp, and invited investors to an on-site Investor Session on June 18, 2026.
Sign In
Buy GLASF
